FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2297499338> ?p ?o ?g. }

• W2297499338 endingPage "1282" @default.
• W2297499338 startingPage "1274" @default.
• W2297499338 abstract "Background Brugada syndrome (BrS) is an arrhythmogenic disease associated with sudden cardiac death (SCD) that seldom manifests or is recognized in childhood. Objectives The objectives of this study were to describe the clinical presentation of pediatric BrS to identify prognostic factors for risk stratification and to propose a data-based approach management. Methods We studied 106 patients younger than 19 years at diagnosis of BrS enrolled from 16 European hospitals. Results At diagnosis, BrS was spontaneous (n = 36, 34%) or drug-induced (n = 70, 66%). The mean age was 11.1 ± 5.7 years, and most patients were asymptomatic (family screening, (n = 67, 63%; incidental, n = 13, 12%), while 15 (14%) experienced syncope, 6(6%) aborted SCD or symptomatic ventricular tachycardia, and 5 (5%) other symptoms. During follow-up (median 54 months), 10 (9%) patients had life-threatening arrhythmias (LTA), including 3 (3%) deaths. Six (6%) experienced syncope and 4 (4%) supraventricular tachycardia. Fever triggered 27% of LTA events. An implantable cardioverter-defibrillator was implanted in 22 (21%), with major adverse events in 41%. Of the 11 (10%) patients treated with hydroquinidine, 8 remained asymptomatic. Genetic testing was performed in 75 (71%) patients, and SCN5A rare variants were identified in 58 (55%); 15 of 32 tested probands (47%) were genotype positive. Nine of 10 patients with LTA underwent genetic testing, and all were genotype positive, whereas the 17 SCN5A-negative patients remained asymptomatic. Spontaneous Brugada type 1 electrocardiographic (ECG) pattern (P = .005) and symptoms at diagnosis (P = .001) were predictors of LTA. Time to the first LTA event was shorter in patients with both symptoms at diagnosis and spontaneous Brugada type 1 ECG pattern (P = .006). Conclusion Spontaneous Brugada type 1 ECG pattern and symptoms at diagnosis are predictors of LTA events in the young affected by BrS. The management of BrS should become age-specific, and prevention of SCD may involve genetic testing and aggressive use of antipyretics and quinidine, with risk-specific consideration for the implantable cardioverter-defibrillator. Brugada syndrome (BrS) is an arrhythmogenic disease associated with sudden cardiac death (SCD) that seldom manifests or is recognized in childhood. The objectives of this study were to describe the clinical presentation of pediatric BrS to identify prognostic factors for risk stratification and to propose a data-based approach management. We studied 106 patients younger than 19 years at diagnosis of BrS enrolled from 16 European hospitals. At diagnosis, BrS was spontaneous (n = 36, 34%) or drug-induced (n = 70, 66%). The mean age was 11.1 ± 5.7 years, and most patients were asymptomatic (family screening, (n = 67, 63%; incidental, n = 13, 12%), while 15 (14%) experienced syncope, 6(6%) aborted SCD or symptomatic ventricular tachycardia, and 5 (5%) other symptoms. During follow-up (median 54 months), 10 (9%) patients had life-threatening arrhythmias (LTA), including 3 (3%) deaths. Six (6%) experienced syncope and 4 (4%) supraventricular tachycardia. Fever triggered 27% of LTA events. An implantable cardioverter-defibrillator was implanted in 22 (21%), with major adverse events in 41%. Of the 11 (10%) patients treated with hydroquinidine, 8 remained asymptomatic. Genetic testing was performed in 75 (71%) patients, and SCN5A rare variants were identified in 58 (55%); 15 of 32 tested probands (47%) were genotype positive. Nine of 10 patients with LTA underwent genetic testing, and all were genotype positive, whereas the 17 SCN5A-negative patients remained asymptomatic. Spontaneous Brugada type 1 electrocardiographic (ECG) pattern (P = .005) and symptoms at diagnosis (P = .001) were predictors of LTA. Time to the first LTA event was shorter in patients with both symptoms at diagnosis and spontaneous Brugada type 1 ECG pattern (P = .006). Spontaneous Brugada type 1 ECG pattern and symptoms at diagnosis are predictors of LTA events in the young affected by BrS. The management of BrS should become age-specific, and prevention of SCD may involve genetic testing and aggressive use of antipyretics and quinidine, with risk-specific consideration for the implantable cardioverter-defibrillator." @default.
• W2297499338 created "2016-06-24" @default.
• W2297499338 creator A5001969191 @default.
• W2297499338 creator A5011046385 @default.
• W2297499338 creator A5013593477 @default.
• W2297499338 creator A5017101104 @default.
• W2297499338 creator A5020654696 @default.
• W2297499338 creator A5021994330 @default.
• W2297499338 creator A5027515638 @default.
• W2297499338 creator A5033510265 @default.
• W2297499338 creator A5033542384 @default.
• W2297499338 creator A5034392769 @default.
• W2297499338 creator A5051740188 @default.
• W2297499338 creator A5052609880 @default.
• W2297499338 creator A5054089467 @default.
• W2297499338 creator A5063961975 @default.
• W2297499338 creator A5064651296 @default.
• W2297499338 creator A5065822560 @default.
• W2297499338 creator A5076644064 @default.
• W2297499338 creator A5076706439 @default.
• W2297499338 creator A5079051225 @default.
• W2297499338 creator A5080007807 @default.
• W2297499338 creator A5088293690 @default.
• W2297499338 creator A5089464289 @default.
• W2297499338 date "2016-06-01" @default.
• W2297499338 modified "2023-10-16" @default.
• W2297499338 title "Impact of clinical and genetic findings on the management of young patients with Brugada syndrome" @default.
• W2297499338 cites W1540071197 @default.
• W2297499338 cites W1649808976 @default.
• W2297499338 cites W175934965 @default.
• W2297499338 cites W1958684831 @default.
• W2297499338 cites W1975642398 @default.
• W2297499338 cites W1991572483 @default.
• W2297499338 cites W1992970209 @default.
• W2297499338 cites W1997696957 @default.
• W2297499338 cites W2001847491 @default.
• W2297499338 cites W2017896912 @default.
• W2297499338 cites W2036655677 @default.
• W2297499338 cites W2040779742 @default.
• W2297499338 cites W2046336333 @default.
• W2297499338 cites W2047827544 @default.
• W2297499338 cites W2078311582 @default.
• W2297499338 cites W2093205427 @default.
• W2297499338 cites W2122455147 @default.
• W2297499338 cites W2127959045 @default.
• W2297499338 cites W2128734390 @default.
• W2297499338 cites W2131195906 @default.
• W2297499338 cites W2131871260 @default.
• W2297499338 cites W2133982161 @default.
• W2297499338 cites W2139997566 @default.
• W2297499338 cites W2146739569 @default.
• W2297499338 cites W2158711990 @default.
• W2297499338 cites W220488953 @default.
• W2297499338 cites W2548446013 @default.
• W2297499338 cites W4211149909 @default.
• W2297499338 doi "https://doi.org/10.1016/j.hrthm.2016.02.013" @default.
• W2297499338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26921764" @default.
• W2297499338 hasPublicationYear "2016" @default.
• W2297499338 type Work @default.
• W2297499338 sameAs 2297499338 @default.
• W2297499338 citedByCount "82" @default.
• W2297499338 countsByYear W22974993382016 @default.
• W2297499338 countsByYear W22974993382017 @default.
• W2297499338 countsByYear W22974993382018 @default.
• W2297499338 countsByYear W22974993382019 @default.
• W2297499338 countsByYear W22974993382020 @default.
• W2297499338 countsByYear W22974993382021 @default.
• W2297499338 countsByYear W22974993382022 @default.
• W2297499338 countsByYear W22974993382023 @default.
• W2297499338 crossrefType "journal-article" @default.
• W2297499338 hasAuthorship W2297499338A5001969191 @default.
• W2297499338 hasAuthorship W2297499338A5011046385 @default.
• W2297499338 hasAuthorship W2297499338A5013593477 @default.
• W2297499338 hasAuthorship W2297499338A5017101104 @default.
• W2297499338 hasAuthorship W2297499338A5020654696 @default.
• W2297499338 hasAuthorship W2297499338A5021994330 @default.
• W2297499338 hasAuthorship W2297499338A5027515638 @default.
• W2297499338 hasAuthorship W2297499338A5033510265 @default.
• W2297499338 hasAuthorship W2297499338A5033542384 @default.
• W2297499338 hasAuthorship W2297499338A5034392769 @default.
• W2297499338 hasAuthorship W2297499338A5051740188 @default.
• W2297499338 hasAuthorship W2297499338A5052609880 @default.
• W2297499338 hasAuthorship W2297499338A5054089467 @default.
• W2297499338 hasAuthorship W2297499338A5063961975 @default.
• W2297499338 hasAuthorship W2297499338A5064651296 @default.
• W2297499338 hasAuthorship W2297499338A5065822560 @default.
• W2297499338 hasAuthorship W2297499338A5076644064 @default.
• W2297499338 hasAuthorship W2297499338A5076706439 @default.
• W2297499338 hasAuthorship W2297499338A5079051225 @default.
• W2297499338 hasAuthorship W2297499338A5080007807 @default.
• W2297499338 hasAuthorship W2297499338A5088293690 @default.
• W2297499338 hasAuthorship W2297499338A5089464289 @default.
• W2297499338 hasBestOaLocation W22974993384 @default.
• W2297499338 hasConcept C126322002 @default.
• W2297499338 hasConcept C164705383 @default.
• W2297499338 hasConcept C187212893 @default.
• W2297499338 hasConcept C2775935837 @default.
• W2297499338 hasConcept C2776331378 @default.

• next